NovaBay [NBY] vs Regeneron [REGN] Detailed Stock Comparison

NovaBay Pharmaceuticals, Inc.

NYSE
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: NovaBay Pharmaceuticals, Inc. wins in 6 metrics, Regeneron Pharmaceuticals, Inc. wins in 10 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric NovaBay Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) 0.04 18.00 NovaBay Pharmaceuticals, Inc.
Price-to-Book Ratio N/A 2.45 N/A
Debt-to-Equity Ratio -0.03 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio -2.38 -4.80 NovaBay Pharmaceuticals, Inc.
EV/EBITDA -5.95 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 0.00% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) 350.10% 23.13% NovaBay Pharmaceuticals, Inc.
EBITDA Margin (TTM) 350.10% 23.13% NovaBay Pharmaceuticals, Inc.
Return on Equity 95.53% 14.86% NovaBay Pharmaceuticals, Inc.
Return on Assets (TTM) -76.11% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-8.43M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return -53.82% 25.39% Regeneron Pharmaceuticals, Inc.
Price-to-Sales Ratio (TTM) N/A 5.50 N/A
Enterprise Value $45.09M $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio N/A 4.95 N/A
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $0 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-28.50 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 0.16 0.40 NovaBay Pharmaceuticals, Inc.
Short % of Float 9.79% 2.55% Regeneron Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

NBY
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
NovaBay Pharmaceuticals, Inc.0.87%-17.14%-11.45%-21.62%-78.11%-96.05%
Regeneron Pharmaceuticals, Inc.2.66%-1.40%-12.73%-19.27%-14.47%-20.27%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
NovaBay Pharmaceuticals, Inc.-53.82%-98.79%-99.97%-99.99%-100.00%-100.00%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: NovaBay Pharmaceuticals, Inc. vs Regeneron Pharmaceuticals, Inc.

MetricNBYREGN
Market Information
Market Cap i$34.35M$80.98B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i186,830642,495
90 Day Avg. Volume i486,346617,765
Last Close$1.16$618.95
52 Week Range$1.08 - $99.75$476.49 - $821.11
% from 52W High-98.84%-24.62%
All-Time High$130,156.25 (Oct 22, 2007)$1,211.20 (Aug 26, 2024)
% from All-Time High-100.00%-48.90%
Growth Metrics
Quarterly Revenue Growth-2.00%0.03%
Quarterly Earnings Growth-1.23%-0.08%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i3.50%0.23%
Return on Equity (TTM) i0.96%0.15%
Debt to Equity (MRQ) i-0.039.51
Cash & Liquidity
Book Value per Share (MRQ)$-0.92$304.65
Cash per Share (MRQ)$0.30$83.86
Operating Cash Flow (TTM) i$2.70M$4.98B
Levered Free Cash Flow (TTM) i$-4,935,750$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend i$0.00$4.46

Valuation & Enterprise Metrics Analysis: NovaBay Pharmaceuticals, Inc. vs Regeneron Pharmaceuticals, Inc.

MetricNBY (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i0.0418.00
Forward P/E i-2.3814.21
PEG Ratio i-2.38-4.80
Price to Sales (TTM) iN/A5.50
Price to Book (MRQ) iN/A2.45
Market Capitalization
Market Capitalization i$34.35M$80.98B
Enterprise Value i$45.09M$70.98B
Enterprise Value Metrics
Enterprise to Revenue iN/A4.95
Enterprise to EBITDA i-5.9516.72
Risk & Other Metrics
Beta i0.160.40
Book Value per Share (MRQ) i$-0.92$304.65

Financial Statements Comparison: NovaBay Pharmaceuticals, Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNBY (2025)REGN (2025)
Revenue/Sales i014.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i-14.6%
Gross Profit iN/A12.24B
Gross Margin i-85.4%
Research & Development iN/A5.85B
Operating Income (EBIT) i-7.59M3.70B
Operating Margin i-25.8%
EBITDA i-7.47M5.00B
EBITDA Margin i-34.8%
Pre-Tax Income i-33.22M5.23B
Pre-Tax Income % of Revenue i-36.5%
Income Tax iN/A725.80M
Income Tax % of Revenue i-5.1%
Net Income (Profit) i-22.14M4.50B
Profit Margin i-31.4%

Balance Sheet & Liquidity Metrics

MetricNBY (2025)REGN (2025)
Cash & Equivalents i7.96M3.12B
Total Current Assets i8.68M18.02B
Total Current Assets % of Revenue i-125.7%
Total Current Liabilities i1.14M4.37B
Total Current Liabilities % of Revenue i-30.5%
Long-Term Debt i287,0002.71B
Long-Term Debt % of Revenue i-18.9%
Total Shareholders Equity i-23.18M31.26B
Retained Earnings i-210.42M35.80B
Retained Earnings % of Revenue i-249.6%
Property, Plant & Equipment i01.54B

Cash Flow Statement Comparison

MetricNBY (2025)REGN (2025)
Operating Cash Flow i-33.33M6.30B
Operating Cash Flow % of Revenue i-43.9%
Capital Expenditures iN/A0
Free Cash Flow i-8.43M3.77B
FCF Margin i-26.3%
Debt Repayment i-2.50MN/A
Common Stock Repurchase i-175,000-3.97B

Short Interest & Institutional Ownership Analysis

MetricNBYREGN
Shares Short i333,1202.55M
Short Ratio i0.694.46
Short % of Float i9.79%2.55%
Shares Outstanding i25.22M105.72M
Float Shares i2.62M98.55M
% Held by Insiders i90.14%1.98%
% Held by Institutions i5.34%91.08%
% Held by Public i4.52%6.94%

Dividend Analysis & Yield Comparison: NovaBay Pharmaceuticals, Inc. vs Regeneron Pharmaceuticals, Inc.

MetricNBYREGN
Last 12-Month Dividend i$0.00$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend i$0.00$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends i$0.00$4.46
Ex-Dividend DateN/AFeb 20, 2026